These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16420781)

  • 1. Health economic issues in MS.
    Kobelt G
    Int MS J; 2006 Jan; 13(1):17-26, 16. PubMed ID: 16420781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economic issues in rheumatoid arthritis.
    Kobelt G
    Scand J Rheumatol; 2006; 35(6):415-25. PubMed ID: 17343248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
    Rotstein Z; Hazan R; Barak Y; Achiron A
    Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of disease-modifying therapies in multiple sclerosis.
    Manouchehrinia A; Constantinescu CS
    Curr Neurol Neurosci Rep; 2012 Oct; 12(5):592-600. PubMed ID: 22782520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managed care aspects of managing multiple sclerosis.
    Owens GM
    Am J Manag Care; 2013 Nov; 19(16 Suppl):s307-12. PubMed ID: 24494620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost of multiple sclerosis in Australia.
    Taylor B; McDonald E; Fantino B; Sedal L; MacDonnell R; Pittas F; Groom T; Beresniak A
    J Clin Neurosci; 2007 Jun; 14(6):532-9. PubMed ID: 17430777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of multiple sclerosis in the Czech Republic: the COMS study.
    Blahova Dusankova J; Kalincik T; Dolezal T; Kobelt G; Havrdova E
    Mult Scler; 2012 May; 18(5):662-8. PubMed ID: 21965424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
    J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconsidering the economic value of multiple sclerosis therapies.
    Shih T; Wakeford C; Meletiche D; Sussell J; Chung A; Liu Y; Shim JJ; Lakdawalla D
    Am J Manag Care; 2016 Nov; 22(11):e368-e374. PubMed ID: 27849348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic burden of multiple sclerosis and the role of managed sare organizations in multiple sclerosis management.
    Owens GM
    Am J Manag Care; 2016 Jun; 22(6 Suppl):s151-8. PubMed ID: 27356024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.
    Caloyeras JP; Zhang B; Wang C; Eriksson M; Fredrikson S; Beckmann K; Knappertz V; Pohl C; Hartung HP; Shah D; Miller JD; Sandbrink R; Lanius V; Gondek K; Russell MW
    Clin Ther; 2012 May; 34(5):1132-44. PubMed ID: 22541587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The cost of treatment of multiple sclerosis in Colombia].
    Romero M; Arango C; Alvis N; Suarez JC; Duque A
    Value Health; 2011; 14(5 Suppl 1):S48-50. PubMed ID: 21839899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project.
    Tinelli M; Pugliatti M; Antonovici A; Hausmann B; Hellwig K; Quoidbach V; Sørensen PS
    Mult Scler Relat Disord; 2021 Sep; 54():103107. PubMed ID: 34237560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
    Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
    Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost of multiple sclerosis in France].
    Fromont A; Lehanneur MN; Rollot F; Weill A; Clerc L; Bonithon Kopp C; Binquet C; Moreau T
    Rev Neurol (Paris); 2014; 170(6-7):432-9. PubMed ID: 24856285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of multiple sclerosis in Australia in 2010.
    Palmer AJ; Colman S; O'Leary B; Taylor BV; Simmons RD
    Mult Scler; 2013 Oct; 19(12):1640-6. PubMed ID: 23652216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain health: time matters in multiple sclerosis.
    Giovannoni G; Butzkueven H; Dhib-Jalbut S; Hobart J; Kobelt G; Pepper G; Sormani MP; Thalheim C; Traboulsee A; Vollmer T
    Mult Scler Relat Disord; 2016 Sep; 9 Suppl 1():S5-S48. PubMed ID: 27640924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.